Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 9/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 2/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | CCKAR | P32238 | 2/20 | 0.46 |
| ▸ | CCKBR | P32239 | 2/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4861889 | 0.91 | HRH2 (0.45) | SCN9ACYP3A4ACE | |
| SCHEMBL4864001 | 0.91 | SCN9A (0.52) | SCN9ACYP3A4CTSSCTSLCTSB | |
| SCHEMBL4868037 | 0.82 | HRH2 (0.46) | SCN9ACYP3A4CTSLACE | |
| SCHEMBL3054407 | 0.80 | SCN9A (0.64) | SCN9ACTSSCTSLCTSBCTSK | |
| SCHEMBL4871937 | 0.79 | SCN9A (0.52) | SCN9ACTSSCTSLCTSBCTSK | |
| SCHEMBL27424651 | 0.79 | CTSS (0.57) | SCN9ACTSSCTSLCTSBCTSK | |
| SCHEMBL27424652 | 0.79 | CTSS (0.57) | SCN9ACTSSCTSLCTSBCTSK | |
| SCHEMBL3957208 | 0.78 | SCN9A (0.58) | SCN9ACTSSCTSLCTSBCTSK | |
| SCHEMBL4868278 | 0.78 | SCN9A (0.53) | SCN9ACTSSCTSLCTSBCTSK | |
| SCHEMBL7274495 | 0.78 | CTSS (0.60) | SCN9ACTSSCTSLCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439394-B2 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2008-10-21 | — | — | US | claimed |
| US-20070117803-A1 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-05-24 | — | — | US | claimed |
| EP-1751090-B1 | ACID DERIVATIVES OF SUBSTITUTED CYCLOHEXYL-1,4-DIAMINES | GRUENENTHAL GMBH (DE) | 2014-10-08 | — | — | EP | disclosed |
| US-7439394-B2 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2008-10-21 | — | — | US | disclosed |
| US-20070117803-A1 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117803-A1 | Cyclohexyl-1,4-diamine compounds | PKD1, DDC, DPYD | SCN9A 1111/4885CYP3A4 335/4885CTSS 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.